Additional recurrent alterations in this tumor class comprised PIK3CA mutations (6/19; 32%), including classical hotspot mutations such as p.H1047 or p.E545, which are known predictive markers for treatment with PIK3 pathway inhibitors in breast cancer25,26. Here, PIK3CG is linked to medical procedure.